Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc reports consumer health developments across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's news commonly covers product launches and brand activity for names such as Sensodyne, parodontax, Centrum, Advil, TUMS, Theraflu, Voltaren, Polident and Panadol.
Recurring updates include oral-care innovation, multivitamin research, consumer marketing campaigns, regional growth initiatives, manufacturing investment, and leadership changes within the U.S. and other markets. As a foreign issuer with American depositary shares traded under HLN, company announcements may also address parent-company reporting, governance and capital-market communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Excedrin has launched the Head Care Club, a program designed to support everyday head health with routines from Emmy Award-winning choreographer Derek Hough. Research indicates that 70% of those experiencing migraines report a negative impact on their quality of life. The program promotes a holistic approach, encouraging proactive measures beyond just treating migraine attacks.
The new Head Care product line includes a daily dietary supplement and nutrient mixes aimed at improving head health. It emphasizes the need for mindfulness, nutrition, and movement to manage headaches and migraines effectively. Dr. Deena Kuruvilla, a neurologist, supports these methods, highlighting their potential benefits for overall brain health. Excedrin aims to enhance well-being via small lifestyle adjustments, reflecting its commitment to comprehensive headache management.
Haleon plc announced the redemption of its total outstanding $300 million Callable Floating Rate Senior Notes due 2024 by its subsidiary, GSK Consumer Healthcare Capital US LLC. The redemption is set for March 24, 2023, at a price equal to 100% of the principal amount plus any accrued interest. All noteholders will receive a notice of redemption from the trustee, Deutsche Bank Trust Company Americas, and the notes must be surrendered to collect the redemption price. This move underlines Haleon's financial strategy as it manages its debt obligations.
Haleon plc (LSE: HLN, NYSE: HLN) announced the expiration and final results of its exchange offers for seven series of unregistered notes issued by GSK Consumer Healthcare Capital. The offers, launched on September 29, 2022, expired on October 28, 2022. The Exchange Notes, which have been registered under the Securities Act, will replace the Original Notes. Settlement is expected on November 2, 2022. The primary aim was to provide holders of Original Notes with registered securities, eliminating prior transfer restrictions.
Haleon and Microsoft have partnered to enhance health product accessibility for individuals who are blind or have low vision. Launched on World Sight Day, the collaboration improves the Microsoft Seeing AI app, enabling detailed audio narrations for over 1,500 Haleon products across the U.S. and U.K. Users can scan barcodes to receive crucial information about product name, ingredients, and usage. This initiative aims to empower users in managing their health independently. Haleon also introduced its Health Inclusivity Index, aiming to enhance global health inclusivity.
Haleon plc (LSE: HLN, NYSE: HLN) announced the start of exchange offers for seven series of outstanding unregistered notes from GSK Consumer Healthcare Capital. The offers aim to exchange these unregistered notes for registered notes under the Securities Act, expected to be listed on the NYSE. The exchange period ends at 5:00 p.m. (Eastern time) on October 28, 2022, with settlement anticipated on November 2, 2022. A registration statement related to the exchange notes was filed with the SEC on the same date.